![]() ![]() ![]() Nexus Oncology has nearly 100 staff across Europe and North America. For more information about Ockham, visit ABOUT NEXUSįounded in 1999, Nexus Oncology offers specialist clinical research services to biopharmaceutical companies developing new cancer treatments. Ockham is headquartered in Cary, North Carolina with satellite offices strategically placed around the United States, India and the United Kingdom to service global customers and operations. Ockham provides its clients with a combination of medical and technical expertise within their tightly controlled clinical studies. The company offers a full range of clinical research services for Phase I-IV clinical trials in oncology, as well as other therapeutic areas. Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986. We are enthusiastic about the macro trends in the pharmaceutical outsourcing industry and we are excited to be Ockham’s financing partner.” Donoghue, General Partner and co-Founder of SCP remarked “We believe that Jim and his team are poised for significant future growth. We expect more great things from Ockham and were thrilled to assist in completing the transaction and introducing Ockham to the great team at SCP.” Reed, Director at Fairmount added “Ockham is now ideally positioned to offer its drug sponsor clients a complete suite of outsourcing capabilities including clinical research staffing, functional service provider and full service CRO project management. Our financing partnership with SCP will enable us to execute on our aggressive future growth plans.”ĭavid K. With our existing operations in North America, Europe and India, we can service our clients on global trials. Baker, CEO of Ockham said “The acquisition of Nexus is a milestone in the history of Ockham, providing us the ability to sharpen our oncology therapeutic expertise and to significantly expand our global clinical trials management platform. The proceeds from the combined financing are being used to provide corporate working capital and to support the acquisition of Nexus. Fairmount introduced Ockham to Spring Capital Partners (“SCP”) and structured the financing which consisted of a $4.5 million mezzanine debt investment from SCP and a senior debt facility. Fairmount Partners served as investment banker and advisor to Ockham. (“Ockham”) announced today its acquisition of Nexus Oncology Ltd (“Nexus”), an Edinburgh, Scotland based CRO focused in oncology. Cary, NC – Ockham Development Group, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |